BR Biopharma (BRBI) versus Its Peers Critical Comparison

BR Biopharma (NASDAQ:BRBI) is one of 1,748 public companies in the “Capital Markets” industry, but how does it contrast to its rivals? We will compare BR Biopharma to related businesses based on the strength of its analyst recommendations, profitability, valuation, earnings, dividends, risk and institutional ownership.

Profitability

This table compares BR Biopharma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BR Biopharma	N/A	N/A	N/A
BR Biopharma Competitors	273.40%	78.32%	3.52%

Dividends

BR Biopharma pays an annual dividend of $0.42 per share and has a dividend yield of 3.7%. BR Biopharma pays out 525.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Capital Markets” companies pay a dividend yield of 3.2% and pay out 30.7% of their earnings in the form of a dividend.

Institutional & Insider Ownership

30.5% of shares of all “Capital Markets” companies are held by institutional investors. 29.4% of BR Biopharma shares are held by insiders. Comparatively, 13.0% of shares of all “Capital Markets” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares BR Biopharma and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BR Biopharma	$2.23 billion	$31.36 million	140.01
BR Biopharma Competitors	$2.39 billion	$396.21 million	7.34

BR Biopharma’s rivals have higher revenue and earnings than BR Biopharma. BR Biopharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings and target prices for BR Biopharma and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BR Biopharma	1	0	0	0	1.00
BR Biopharma Competitors	5393	19748	21931	614	2.37

As a group, “Capital Markets” companies have a potential upside of 29.26%. Given BR Biopharma’s rivals stronger consensus rating and higher probable upside, analysts clearly believe BR Biopharma has less favorable growth aspects than its rivals.

Summary

BR Biopharma rivals beat BR Biopharma on 11 of the 14 factors compared.

About BR Biopharma

BRBI BR Partners S.A., through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners S.A. is based in S?o Paulo, Brazil.